Proactive Research analyst Robin Davison presents his report on Poolbeg Pharma PLC (AIM:POLB) (Poolbeg Pharma PLC (AIM:POLB)) after the company announced an in-licensed a potential immunotherapy for respiratory virus infections such as influenza and coronavirus from the University of Warwick.
The RNA-based drug works by triggering nasal cells into an antiviral state to protect from the infecting virus. Simultaneously, it blocks the cells from making more virus by directly preventing replication.
Based on the research of professors Andrew Easton and Nigel Dimmock, the asset is at a late-pre-clinical development stage. It will join the Poolbeg pipeline as POLB 002.